Leadership
Matt Angel
President and Chief Executive Officer
Dr. Angel, age 45, has served as Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors of Factor Bioscience Inc. since 2011. From January 2023 to December 2023, Dr. Angel served as President and Chief Executive Officer and as a director of Ernexa Therapeutics Inc. (f/k/a Eterna Therapeutics Inc.). From May 2022 to December 2022, Dr. Angel served as Interim President, Chief Executive Officer and as a director of Ernexa Therapeutics Inc. In 2020, Dr. Angel co-founded Exacis Biotherapeutics Inc. (“Exacis”) and served as the Chief Science Officer, Secretary, Treasurer and as a director of Exacis from 2020 until the sale of Exacis in May 2023. Dr. Angel also co-founded and served as the Chief Science Officer, Secretary and as a director of Novellus, Inc., from 2014 until the sale of Novellus in July 2021. Dr. Angel received a Ph.D. from the Massachusetts Institute of Technology in 2012 and a B.S. in Engineering from Princeton University in 2003.
Andrew Fang, Ph.D.
Head of Business Development
Andrew Fang, Ph.D., is Co-founder of Tempest Therapeutics and Founding Partner of YQ Advisors, where he focuses on strategic transactions and value creation in biotech and emerging technologies. He brings deep experience across cross-border licensing, asset transactions, biotech financings, and public-company strategic situations. Prior to founding YQ Advisors, Dr. Fang spent eight years at CEC Capital, where he served as Executive Director in healthcare investment banking and worked on a broad range of private placements, cross-border financings, and strategic transactions for biotechnology companies. His transaction experience includes work with innovative and late-stage clinical-stage companies such as iRegene, Connect Biopharma, Everest Medicines, Haihe Biopharma, Arctic Vision, and other public and venture-backed biopharma companies. At YQ Advisors, he focuses on ex-China/global licensing, M&A and reverse merger opportunities involving public biotech companies, and the incubation of early-stage biotech platforms, particularly in cell and gene therapy and AI-enabled biotech. Dr. Fang holds a Ph.D. in Chemical & Chemical Biology from Rutgers University and a bachelor’s degree in Materials Science from the University of Science and Technology of China.